Jason Liebowitz, MD, completed his fellowship in rheumatology at Johns Hopkins University, Baltimore, where he also earned his medical degree. He is currently in practice with Skylands Medical Group, N.J.
References
- U.S. Food & Drug Administration. Medical product safety information: Remdesivir by Gilead Sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment. 2020 Jun 15.
- Tselios K, Gladman DD, Urowitz MB. How can we define low disease activity in systemic lupus erythematosus? Semin Arthritis Rheum. 2019 Jun;48(6):1035–1040.
- Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020 Sep 17;383(12):1117–1128.
- Arriens C, Polyakova S, Adzerikho I, et al. AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (oral presentation: OP0277). Ann Rheum Dis. 2020;79:172–173.
